Apiruk After a volatile journey in the last 12 months, shares of TG Therapeutics (NASDAQ:TGTX) have recovered and hit resistance levels in the low 20s again. The company will report second quarter results within the next 10 days (the earnings report is not scheduled yet as TG gives very short notice about the timing lately) and while I wrote that there is now less room for doubt about Briumvi after the first quarter earnings report, it needs to continue to outperform Street expectations if the stock is  ...